Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance

SUPERNUS PHARMACEUTICALS, INC.

2024-Q2 EPS reported $0.36 revenue$311,969,000

Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)
Operating income $22.6M; adjusted operating earnings $45.5M, up from $10.0M in Q2 2023
Raising full-year 2024 guidance for total revenues and operating earnings (GAAP and non-GAAP)
Resubmitted NDA for apomorphine infusion device (SPN-830) for Parkinson's motor fluctuations
Phase 2b trial of SPN-820 for TRD expected topline data H1 2025; Phase 2 open-label MDD data by end 2024

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.